STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study
Eli Lilly announced that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 28 09:42 ETSource: STAT
From the source
Read at statnews.comSTAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study
Eli Lilly announced that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study.
